MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517055936 A) filed by Merck Sharp & Dohme Llc, Rahway, U.S.A., on June 10, for '2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide derivatives as protease inhibitors for treating or preventing coronavirus infection.'
Inventor(s) include Acton III, John J; Gupta, Mayuri; Kelly III, Michael J.; Klingler, Franca-Maria; Layton, Mark Eric; Mccauley, John A.; Morriello, Gregori J; Nawrat, Christopher Charles; Parish, Craig A.; Roecker, Anthony J.; De Lera Ruiz, Manuel; Su, Jing; Shurtleff, Valerie W.; and Truong, Quang T.
The application for the patent was published on July 4, under issue no. 27/2025.
According to the abstract released by the Intellectual Property India: "The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof."
The patent application was internationally filed on Nov. 20, 2023, under International application No.PCT/US2023/080450.
Disclaimer: Curated by HT Syndication.
